Park Avenue Securities LLC Acquires 538 Shares of IQVIA Holdings Inc. $IQV

Park Avenue Securities LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 5,963 shares of the medical research company’s stock after buying an additional 538 shares during the quarter. Park Avenue Securities LLC’s holdings in IQVIA were worth $940,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Pacer Advisors Inc. grew its holdings in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after purchasing an additional 798,534 shares during the last quarter. Hawk Ridge Capital Management LP bought a new stake in IQVIA in the 1st quarter worth $77,096,000. Nuveen LLC bought a new stake in IQVIA in the 1st quarter worth $76,328,000. Finally, GAMMA Investing LLC grew its holdings in IQVIA by 27,448.4% in the 1st quarter. GAMMA Investing LLC now owns 387,331 shares of the medical research company’s stock worth $68,286,000 after acquiring an additional 385,925 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. UBS Group raised their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Robert W. Baird raised their price target on shares of IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Barclays raised their price target on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Finally, Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $229.64.

IQVIA Trading Up 1.6%

NYSE:IQV opened at $179.51 on Friday. The company has a 50-day moving average price of $187.01 and a 200-day moving average price of $167.15. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $237.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a market cap of $30.52 billion, a price-to-earnings ratio of 25.98, a P/E/G ratio of 1.97 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same period last year, the company posted $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.